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Results: At week 12, PSSI 90 (secukinumab 300 mg vs placebo, 52.9% vs 2.0%) and Investigator's Global Assessment modified 2011 scalp responses of 0 or 1 (secukinumab 300 mg vs placebo, 56.9% vs 5.9%) were significantly greater with secukinumab 300 mg than placebo (P \ .001 for both). In addition, significantly more patients achieved complete clearance of scalp psoriasis at week 12 with secukinumab 300 mg than placebo (35.3% vs 0%; P \ .001). The median time to 50% reduction in PSSI score was 3.29 weeks with secukinumab 300 mg. The safety profile of secukinumab was consistent with previous phase 3 studies.
Limitations: There was no active comparator arm.
Conclusion:
Secukinumab is efficacious and well-tolerated for patients with extensive moderate-to-severe scalp psoriasis. ( J Am Acad Dermatol 2017;77:667-74.)
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Scalp psoriasis is estimated to affect up to 80% of patients with psoriasis 1 and involves a strong psychosocial effect, reducing physical and psychologic health irrespective of disease severity in other areas of the body and ultimately reduces quality of life. [2] [3] [4] Topical treatments are less effective on the scalp than other body areas because the scalp is relatively inaccessible and hair makes use of ointments and creambased products challenging, often leading to poor compliance. 1, 5, 6 The efficacy of biologics and small-molecule therapeutics on scalp psoriasis has largely been examined in subgroup analyses of phase 3 clinical trials and retrospective cohort studies. [7] [8] [9] [10] [11] [12] Scalp psoriasis has only been prospectively examined in 1 study of etanercept in moderate-to-severe plaque psoriasis with scalp involvement. 13 To date, all scalp psoriasis studies required concomitant moderate-to-severe body plaque psoriasis and moderate-to-severe scalp psoriasis. The current study examined patients with moderate-to-severe scalp psoriasis without requiring moderate-to-severe body plaque psoriasis.
Secukinumab, a fully human monoclonal antibody that selectively neutralizes interleukin (IL) 17A, has significant efficacy in moderate-to-severe plaque psoriasis, demonstrating a rapid onset of action and sustained responses with a favorable safety profile. [14] [15] [16] Here, we report the efficacy and safety of secukinumab 300 mg over 24 weeks from a prospective phase 3b study of moderate-to-severe scalp psoriasis.
METHODS

Participants
Patients aged $18 years with moderate-to-severe scalp psoriasis (with or without plaque psoriasis elsewhere on the body) of $6 months' duration that was inadequately controlled by topical treatments, phototherapy, or systemic therapies were eligible for this trial. Moderate-to-severe scalp psoriasis was defined as a Psoriasis Scalp Severity Index (PSSI) score of $12 (0-72 scale), with $30% of the scalp surface area affected. Following an amendment to the protocol, newly enrolled patients from February 12, 2015 , and onwards must also have had an Investigator's Global Assessment modified 2011 (IGA mod 2011) 17 (scalp only) score of $3 (0-4 scale). Key exclusion criteria included previous exposure to biologics directly targeting IL-17 or the IL-17 receptor, forms of psoriasis other than chronic plaque psoriasis (eg, erythrodermic and guttate psoriasis), and ongoing use of prohibited psoriasis treatments (eg, topical or systemic corticosteroids, other topical medications, oral or biologic treatments, or ultraviolet therapy).
Study design
This 24-week randomized, double-blind, placebo-controlled, parallel-group, multicenter, phase 3b study (NCT02267135) was conducted according to the ethical principles of the Declaration of Helsinki and Good Clinical Practice. The study protocol was approved by the respective institutional review boards of the 17 obtained from all patients. The study was initiated in September 2014 (first patient, first visit), and was completed in December 2015 (last patient, last visit).
The trial was divided into 3 parts: the screening period (1-4 weeks), treatment period 1 (12 weeks), and treatment period 2 (12 weeks) (Fig 1) . After the screening period, eligible patients were randomized via an interactive response technology system 1:1 to receive secukinumab 300 mg or placebo in identical packaging. Each dose of secukinumab 300 mg or placebo was self-administered by using 2 subcutaneous injections with a single-use prefilled syringe. Patients received secukinumab 300 mg or placebo at baseline, weeks 1, 2, and 3, and then every 4 weeks from week 4 to 20. The final efficacy and safety evaluations were performed at week 24. Placebo-treated patients who achieved a PSSI improvement of 90% (PSSI 90) response at week 12 continued receiving placebo, and those who did not achieve a PSSI 90 response at week 12 switched to treatment with secukinumab 300 mg at weeks 12, 13, 14, 15, 16, and 20. To maintain blinding, patients continuing on secukinumab or placebo from treatment period 1 through treatment period 2 self-administered placebo at weeks 13, 14, and 15. During the study, patients were prohibited from the use of any treatments that could confound the efficacy of secukinumab, including medicated over-the-counter shampoos.
Study objectives
The primary objective was to determine the proportion of patients using secukinumab 300 mg or patients using placebo who achieve a PSSI 90 score at week 12. The key secondary objective was to determine the proportion of patients in each cohort achieving an IGA mod 2011 0 (clear) or 1 (almost clear) response (for the scalp only) at week 12.
Determining the 100% improvement in PSSI score (PSSI 100) response rate at week 12 and time to 50% reduction in PSSI score were also secondary objectives. Safety and tolerability of secukinumab were evaluated by vital signs, clinical laboratory variables, electrocardiogram, and adverse events (AEs) monitoring. The assessment of safety was based mainly on the frequency of AEs and laboratory tests.
Statistical analysis
Efficacy analyses are presented for the full analysis set, comprising all patients to whom study medication was assigned. PSSI 90, PSSI 100, and IGA mod 2011 0 or 1 (scalp only) responses were analyzed by using the Cochran-Mantel-Haenszel test adjusted for body weight (\90 kg or $90 kg) 18 ; the Fisher's exact test was used to calculate the 95% confidence interval (CI) and P value when no responders in any group were observed. For binary efficacy variables, missing values were imputed as nonresponse.
The mean percent change from baseline in PSSI score was calculated by using the last observation carried forward for missing data. The median time to 50% reduction in PSSI score was estimated by using the Kaplan-Meier method, and the treatment groups were compared by using the log-rank test.
A hierarchical hypothesis testing approach was employed for the primary efficacy variable and the key secondary efficacy variable at week 12. If a statistically significant difference (ie, P # .05) between the 2 treatment groups was obtained for the primary efficacy variable, hypothesis testing to compare the 2 treatment groups with respect to the key secondary efficacy variables was performed at the .05 significance level.
Sample size was calculated on the basis of the primary efficacy variable, PSSI 90. We calculated that approximately 94 patients (47 per group) were needed for randomization in a trial with the following parameters: a continuity-corrected x 
RESULTS
Study population
A total of 102 patients were randomized 1:1 to secukinumab 300 mg or placebo (Fig 2) . Of these patients, 97 (95%) completed treatment period 1 and 92 (90%) completed treatment period 2. Only 1 patient randomized to placebo continued to receive placebo during treatment period 2. One protocol deviation of selection criteria occurred, in which 1 patient (1.0%) randomized to secukinumab had not had prior therapy for psoriasis. Baseline demographics and disease characteristics were similar between treatment groups (Table I ). In the overall study population, the mean baseline PSSI score was 33.2, the mean baseline scalp surface area affected was 60.4%, and 43.1% of patients had $70% scalp surface area affected, indicating extensive scalp involvement. All patients in this study had moderate-to-severe scalp disease as measured by IGA mod 2011 rating scale. Although 89.2% of patients had body plaque psoriasis, the overall mean Psoriasis Area and Severity Index (PASI) score (9.24) and body surface area (BSA) affected (11.8%) at baseline were low.
Efficacy
Secukinumab 300 mg demonstrated significantly greater efficacy than placebo for both the primary and key secondary efficacy variables of this trial (Table II) . At week 12, PSSI 90 was achieved by 52.9% of patients receiving secukinumab 300 mg and by 2.0% of patients receiving placebo (difference between proportions: 0.51, 95% CI 0.37-0.65, P \ .001; Fig 3) . Also at week 12, IGA mod 2011 scalp responses of 0 or 1 were achieved by 56.9% of patients receiving secukinumab 300 mg and by 5.9% of patients receiving placebo (difference between proportions: 0.51, 95% CI 0.36-0.66, P \.001).
In addition, a significantly higher proportion of patients achieved complete clearance of scalp psoriasis (PSSI 100) with secukinumab 300 mg than with placebo. At week 12, PSSI 100 was observed in 35.3% of patients receiving secukinumab 300 mg and 0% of patients receiving placebo (difference between proportions: 0.35, 95% CI 0.15-0.53, P \.001). 
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Statistically significant improvements were rapid and observed as early as week 3 for PSSI 90 responses (secukinumab 300 mg vs placebo, 11.8% vs 0%; difference between proportions: 0.12, 95% CI e0.09 to 0.31, P = .027; P value, rather than CI, should be relied upon for Fisher's exact test) and IGA mod 2011 scalp 0 or 1 responses (secukinumab 300 mg vs placebo, 25.5% vs 5.9%; difference between proportions: 0.20, 95% CI 0.06-0.33, P = .005). Furthermore, responses continued to increase up to week 24. At week 24, PSSI 90 was achieved by 58.8% of patients receiving secukinumab 300 mg. Similarly, at week 24, IGA mod 2011 scalp responses of 0 or 1 were achieved by 62.7% and PSSI 100 by 47.1% of patients receiving secukinumab 300 mg.
The mean percent change of the PSSI score from baseline to week 12 is presented in Fig 4. The median time to 50% reduction in PSSI score was 3.29 weeks (95% CI 2.43-8.14) for secukinumab 300 mg; the median was not estimable for placebo because a 50% reduction in PSSI score was not achieved by enough patients receiving placebo.
Safety
No new or unexpected safety signals with secukinumab were observed in this trial, and secukinumab 300 mg was demonstrated to be well tolerated over 24 weeks. The median duration of exposure to study treatment in the secukinumab 300 mg group was 169 days compared with 84 days in the placebo group. Overall, 62 (60.8%) patients experienced $1 AE (secukinumab 300 mg vs placebo, 72.5% vs 49.0%). The most commonly occurring AEs among patients treated with secukinumab 300 mg were nasopharyngitis (5.9%), upper respiratory tract infection (5.9%), cough (5.9%), and contact dermatitis (5.9%, Table III) . Overall, infections and infestations were observed in 29.4% of patients receiving secukinumab 300 mg and 19.6% of patients receiving placebo.
No deaths occurred during this study. Only 1 serious AE (a case of cellulitis in the placebo group) occurred during this 24-week trial. Two patients, both receiving secukinumab 300 mg, discontinued study treatment as a result of AEs (moderate upper abdominal pain and mild psoriasis). No remarkable differences were noted between the secukinumab 300 mg and placebo groups for clinical laboratory evaluations of hematology and clinical chemistry, and no relevant changes in vital signs or electrocardiogram readings were observed in the study.
Throughout the course of this study, there were no cases of major adverse cardiac events, neutropenia grade 3 or 4, malignancy, or inflammatory bowel disease. All treatment-emergent AEs experienced by patients in any group were either mild or moderate in severity. There were 2 Candida infections, 1 in each treatment group. In the secukinumab 300 mg group, 1 patient experienced moderate vulvovaginal candidiasis, which was resolved with treatment and did not lead to discontinuation of secukinumab. Similarly, in the placebo group, 1 patient experienced a Candida infection, which did not lead to discontinuation of study treatment.
DISCUSSION
Secukinumab treatment alone without concomitant scalp psoriasis treatment is efficacious and well tolerated in moderate-to-severe scalp psoriasis. Patients in this trial had extensive scalp involvement at baseline as evidenced by a mean PSSI score of 33.2, a mean affected scalp surface area of 60.4%, and $70% of scalp surface area affected in 43.1% of patients.
Inclusion criteria for this prospective, doubleblind, placebo-controlled trial of secukinumab J AM ACAD DERMATOL VOLUME 77, NUMBER 4 were determined solely by severity of scalp psoriasis without regard to body plaque psoriasis. Previous phase 3 trials of moderate-to-severe plaque psoriasis had mean baseline PASI scores ranging from 19 to 24 and mean BSA involvement of 24%-35%. 14, 19, 20 Most scalp psoriasis studies have been subgroup analyses from phase 3 trials of patients with moderate-to-severe body plaque psoriasis and similar levels of BSA involvement. [8] [9] [10] [11] In addition, these trials often did not evaluate the percentage of scalp surface area affected by psoriasis and concomitant use of certain topical steroids and shampoos was allowed.
10,11 Although 89.2% of patients in this study had body plaque psoriasis at baseline, the mean PASI score was 9.24 and BSA involvement was 11.8%; this study also did not allow use of any topical steroids or shampoos. Therefore, caution should be exercised when making indirect comparisons with other scalp psoriasis studies, which had scalp psoriasis populations that were significantly different from that in this study and had differing concomitant therapy allowances. Both the primary and key secondary objectives of this study were met with secukinumab 300 mg, which provided significantly greater PSSI 90 and IGA mod 2011 scalp 0 or 1 responses than placebo at Patients with missing assessment were considered as nonresponders. P value was calculated using Cochran-Mantel-Haenszel test and adjusted for body weight (\90 kg, $90 kg). The 95% CIs for difference between proportions were calculated using the normal approximation to the binomial distribution. If there were no responders observed in any group then both the 95% CI for difference between proportions and P value were calculated using Fisher's exact test. CI, Confidence interval; IGA mod 2011, Investigator's Global Assessment modified 2011; PSSI, Psoriasis Scalp Severity Index. J AM ACAD DERMATOL week 12. The proportion of patients achieving a PSSI 100 response at week 12 was also significantly greater with secukinumab 300 mg than placebo. These responses were sustained over 24 weeks. Responses to secukinumab were rapid; significant differences measured by PSSI 90 and IGA mod 2011 scalp 0 or 1 responses were observed starting at week 3, and median time to 50% reduction in PSSI score was 3.29 weeks.
No new or unexpected safety signals developed over 24 weeks of treatment with secukinumab. There were no deaths, cases of major adverse cardiac events, neutropenia grades 3 or 4, malignancy, or inflammatory bowel disease. There was a single case of vulvovaginal candidiasis in the secukinumab treatment group, which resolved with treatment and did not lead to discontinuation of secukinumab. The safety profile of secukinumab 300 mg was comparable to the safety of secukinumab treatment in previous phase 3 trials. 14, 16, 21, 22 Limitations of this study include the lack of an active comparator. Future studies directly comparing biologics will be useful in aiding physicians with therapy selection.
Secukinumab 300 mg provided significantly greater clearance of moderate-to-severe scalp psoriasis than placebo. These promising results demonstrate the possibility of establishing PSSI 90 as a new benchmark for scalp psoriasis treatment outcome. Secukinumab is a highly efficacious and well-tolerated treatment for patients with extensive moderate-to-severe scalp psoriasis. Patients in the placebo group who did not achieve Psoriasis Scalp Severity Index 90 at week 12 were administered secukinumab 300 mg for the remainder of the study. Safety data for the placebo group include all patients who received placebo up to week 12 and the 1 patient who continued on placebo up to week 24.
